Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.
Identifieur interne : 000641 ( PubMed/Corpus ); précédent : 000640; suivant : 000642Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.
Auteurs : Martial Mermillod ; Laurie Mondillon ; Isabelle Rieu ; Damien Devaux ; Patrick Chambres ; Catherine Auxiette ; Hélène Dalens ; Louise Marie Coulangeon ; Isabelle Jalenques ; Franck DurifSource :
- Journal of Parkinson's disease [ 1877-718X ] ; 2014.
English descriptors
- KwdEn :
- Affect (physiology), Aged, Antiparkinson Agents (adverse effects), Combined Modality Therapy, Deep Brain Stimulation (adverse effects), Emotions (physiology), Facial Expression, Humans, Levodopa (adverse effects), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Subthalamic Nucleus (surgery).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- adverse effects : Deep Brain Stimulation.
- drug therapy : Parkinson Disease.
- physiology : Affect, Emotions.
- physiopathology : Parkinson Disease.
- surgery : Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Aged, Combined Modality Therapy, Facial Expression, Humans, Middle Aged.
Abstract
Deep brain stimulation of the subthalamic nuclei (STN-DBS) is an effective treatment for the most severe forms of Parkinson's disease (PD) and is intended to suppress these patients' motor symptoms. However, be it in association with Dopamine Replacement Therapy (DRT) or not, STN-DBS may in some cases induce addictive or emotional disorders.
DOI: 10.3233/JPD-130256
PubMed: 24496100
Links to Exploration step
pubmed:24496100Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.</title><author><name sortKey="Mermillod, Martial" sort="Mermillod, Martial" uniqKey="Mermillod M" first="Martial" last="Mermillod">Martial Mermillod</name><affiliation><nlm:affiliation>Université Grenoble Alpes, LPNC, F-38040, Grenoble & CNRS, LPNC UMR 5105, F-38040, Grenoble, France Institut Universitaire de France.</nlm:affiliation></affiliation></author><author><name sortKey="Mondillon, Laurie" sort="Mondillon, Laurie" uniqKey="Mondillon L" first="Laurie" last="Mondillon">Laurie Mondillon</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devaux, Damien" sort="Devaux, Damien" uniqKey="Devaux D" first="Damien" last="Devaux">Damien Devaux</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chambres, Patrick" sort="Chambres, Patrick" uniqKey="Chambres P" first="Patrick" last="Chambres">Patrick Chambres</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Auxiette, Catherine" sort="Auxiette, Catherine" uniqKey="Auxiette C" first="Catherine" last="Auxiette">Catherine Auxiette</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dalens, Helene" sort="Dalens, Helene" uniqKey="Dalens H" first="Hélène" last="Dalens">Hélène Dalens</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Coulangeon, Louise Marie" sort="Coulangeon, Louise Marie" uniqKey="Coulangeon L" first="Louise Marie" last="Coulangeon">Louise Marie Coulangeon</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jalenques, Isabelle" sort="Jalenques, Isabelle" uniqKey="Jalenques I" first="Isabelle" last="Jalenques">Isabelle Jalenques</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Psychiatrie de l'Adulte A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24496100</idno><idno type="pmid">24496100</idno><idno type="doi">10.3233/JPD-130256</idno><idno type="wicri:Area/PubMed/Corpus">000641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000641</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.</title><author><name sortKey="Mermillod, Martial" sort="Mermillod, Martial" uniqKey="Mermillod M" first="Martial" last="Mermillod">Martial Mermillod</name><affiliation><nlm:affiliation>Université Grenoble Alpes, LPNC, F-38040, Grenoble & CNRS, LPNC UMR 5105, F-38040, Grenoble, France Institut Universitaire de France.</nlm:affiliation></affiliation></author><author><name sortKey="Mondillon, Laurie" sort="Mondillon, Laurie" uniqKey="Mondillon L" first="Laurie" last="Mondillon">Laurie Mondillon</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devaux, Damien" sort="Devaux, Damien" uniqKey="Devaux D" first="Damien" last="Devaux">Damien Devaux</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chambres, Patrick" sort="Chambres, Patrick" uniqKey="Chambres P" first="Patrick" last="Chambres">Patrick Chambres</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Auxiette, Catherine" sort="Auxiette, Catherine" uniqKey="Auxiette C" first="Catherine" last="Auxiette">Catherine Auxiette</name><affiliation><nlm:affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dalens, Helene" sort="Dalens, Helene" uniqKey="Dalens H" first="Hélène" last="Dalens">Hélène Dalens</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Coulangeon, Louise Marie" sort="Coulangeon, Louise Marie" uniqKey="Coulangeon L" first="Louise Marie" last="Coulangeon">Louise Marie Coulangeon</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jalenques, Isabelle" sort="Jalenques, Isabelle" uniqKey="Jalenques I" first="Isabelle" last="Jalenques">Isabelle Jalenques</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Psychiatrie de l'Adulte A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of Parkinson's disease</title><idno type="eISSN">1877-718X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Affect (physiology)</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Combined Modality Therapy</term><term>Deep Brain Stimulation (adverse effects)</term><term>Emotions (physiology)</term><term>Facial Expression</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Subthalamic Nucleus (surgery)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Affect</term><term>Emotions</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Combined Modality Therapy</term><term>Facial Expression</term><term>Humans</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Deep brain stimulation of the subthalamic nuclei (STN-DBS) is an effective treatment for the most severe forms of Parkinson's disease (PD) and is intended to suppress these patients' motor symptoms. However, be it in association with Dopamine Replacement Therapy (DRT) or not, STN-DBS may in some cases induce addictive or emotional disorders.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24496100</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>10</Day></DateCreated><DateCompleted><Year>2014</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2014</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1877-718X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of Parkinson's disease</Title><ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>97-110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-130256</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Deep brain stimulation of the subthalamic nuclei (STN-DBS) is an effective treatment for the most severe forms of Parkinson's disease (PD) and is intended to suppress these patients' motor symptoms. However, be it in association with Dopamine Replacement Therapy (DRT) or not, STN-DBS may in some cases induce addictive or emotional disorders.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In the current study, we suggest that PD patients suffer from emotional deficits that have not been revealed in previous studies because in those experiments the stimuli were displayed for a time long enough to allow patients to have recourse to perceptual strategies in order to recognize the emotional facial expressions (EFE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The aim of the current article is to demonstrate the existence of emotional disorders in PD by using a rapid presentation of the visual stimuli (200-ms display time) which curtails their perceptual analysis, and to determine whether STN-DBS, either associated or not associated with DRT, has an impact on the recognition of emotions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results show that EFE recognition performance depends on both STN-DBS ('on' vs. 'off') and medication ('on' vs. 'off'), but also that these variables have an interactive influence on EFE recognition performance. Moreover, we also reveal how these EFE impairments depend on different spatial frequencies perceptual channels (related to different cortical vs. subcortical neural structures).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The effect of PD without therapy seems to be particularly acute for LSF emotional faces, possibly due to a subcortical dysfunction. However, our results indicate that the joint action of STN-DBS and DRT could also disrupt recognition of emotional expressions at the level of occipito-temporal cortical areas (processing HSF visual information) inducing broad global impairment of EFE at the level of HSF visual channels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mermillod</LastName><ForeName>Martial</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université Grenoble Alpes, LPNC, F-38040, Grenoble & CNRS, LPNC UMR 5105, F-38040, Grenoble, France Institut Universitaire de France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mondillon</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieu</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaux</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambres</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auxiette</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Psychologie Sociale et Cognitive, CNRS UMR 6024, Clermont Université, Université Blaise Pascal, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalens</LastName><ForeName>Hélène</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulangeon</LastName><ForeName>Louise Marie</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service d'Ophtalmologie, F-63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalenques</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service de Psychiatrie de l'Adulte A, F-63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service de Neurologie A, F-63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Parkinsons Dis</MedlineTA><NlmUniqueID>101567362</NlmUniqueID><ISSNLinking>1877-7171</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="N">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">deep brain stimulation</Keyword><Keyword MajorTopicYN="N">dopamine replacement therapy</Keyword><Keyword MajorTopicYN="N">emotions</Keyword><Keyword MajorTopicYN="N">spatial frequency information</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24496100</ArticleId><ArticleId IdType="pii">X0005171R5732872</ArticleId><ArticleId IdType="doi">10.3233/JPD-130256</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000641 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000641 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24496100
|texte= Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24496100" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |